SEC Form 4: Northstar Bio Ventures, Llc sold $3,420 worth of shares (570,000 units at $0.01) and acquired 75,000 shares, decreasing direct ownership by 26% to 1,417,500 units
$MTRY
Blank Checks
Finance
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Monterey Innovation Acquisition Corp [ MTRY ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 03/09/2023 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
|||||||||||||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock(1) | 03/09/2023 | S | 570,000(2) | D | $0.006(2) | 1,342,500 | D | |||
| Common Stock(1) | 03/09/2023 | J | 75,000(3) | A | (3) | 1,417,500 | D | |||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Explanation of Responses: |
| 1. This Form 4 is being filed by NorthStar Bio Ventures, LLC (the "NorthStar Co-Sponsor"). Sandip I. Patel is a manager of NorthStar Co-Sponsor. Accordingly, Mr. Patel has voting and dispositive power over the shares of common stock (the "founder shares") of Monterey Innovation Acquisition Corp. (the "Company") held by NorthStar Co-Sponsor and may be deemed to beneficially own such shares. Mr. Patel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 2. In connection with the Company's previously disclosed management transition, and pursuant to share transfer agreements dated March 9, 2023, NorthStar Co-Sponsor transferred (i) 478,125 founder shares to Chardan Monterey Investments LLC and (ii) 30,625 founder shares to each of the Company's three new directors, in each case, at a price of $0.006 per share. |
| 3. On March 9, 2023, Sanjeev Satyal resigned as the Company's Chief Executive Officer and, pursuant to an assignment dated March 9, 2023, transferred back to NorthStar Co-Sponsor 75,000 of the founder shares that he received from NorthStar Co-Sponsor prior to the Company's initial public offering. |
| NorthStar Bio Ventures, LLC By: /s/ Jason T. Simon, as Attorney-in-Fact | 03/13/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||